The rogue DNA rings may be the secret spark that leads the deadly brain cancer

The results published on September 8 in Discovering cancer, It is the first to indicate that ECDNA rings containing genes that lead cancer often appear in the early stages of the development of glial tumor-and in some cases, even before the tumor is completely formed. This early access may pave the way for the rapid growth of cancer, the ability to adapt and resist treatment.

The study was led by Dr. Benjamin Werner at Queen Mary University in London and Professor Paul Michel at Stanford University, both part of the Great Cancer Challenges team, as well as Professor Charlie Suanton at the Francis Kreik Institute.

Treating the most difficult challenges of cancer

Aromi diet is one of the most challenging types of cancer, while average survival remains in about 14 months and a little improvement in recent decades. Urgent need for new approaches to the previous detection and the most effective treatment.

ECDNA appears as an important important player in many adult cancers and children, including an aromatic tumor, but its role is complex and mysterious. The Great Cancer Challenges initiative – founded by cancer research and the National Cancer Institute in the United States – has identified ECDNA as one of the most difficult challenges facing this field today. In 2022, they funded the Edynamic-Consortium team with a value of $ 25 million in cancer experts, clinical research, evolutionary biology, computer and mathematics-and dismantling the role of ECDNA and determining ways to target them. The current study represents an important progress in the work of Team Edynamic.

Dug the tumor

In their new studies, the Edynamic team and their collaboratory merged the genome data and photography from patients with an aromatic tumor with the advanced arithmetic modeling of the ECDNAS development in place and time.

“We have studied tumors like an archaeologist. Instead of taking one sample, we have dug multiple sites around the tumor, allowing us to build mathematical models describing how they evolved. We simulated millions of different scenarios to rebuild adults in adults, and explained the elderly.

The analysis revealed that most ECDNA episodes contain EGFRStrong genes for cancer. EGFR ECDNA appeared early in the development of cancer – even before the tumor is formed in some patients. It also gained additional changes, such as EGFRViii alternative, which made cancer more aggressive and resistant to treatments.

A window of opportunities

“These accurate mechanisms show that there may be a window an opportunity to discover and treat the disease between the first appearance EGFR Dr. Magnus Hawigi, post -PhD researcher at Dr. Werner and one of the authors of the paper. ” EGFR ECDNA – For example, through a blood test – it can enable them to intervene before the disease becomes more difficult. “

The study confirmed that ECDNA can carry more than one cancer gene at one time, each of which may be uniquely how tumors develop and respond to treatment. This highlights the potential value of the treatment of treatments based on the ECDNA file for the tumor.

However, many puzzles remain. Researchers are now planning to study how different treatments affect the number and types of ECDNA in an aromic tumor. Team Edynamic will continue to investigate the role of ECDNAS through a set of cancer types to detect more opportunities to diagnose cancers earlier, track their progress more accurately, and design smarter treatments.

Charlie Suanton, Deputy Clinical Director and Head of Cancer Evolution Laboratory and instability in genome says at the Francis Institute of Crick and chief doctors in cancer research in the United Kingdom ::

“These results indicate that ECDNA is not just a passenger in a bell tumor, but it is an early and powerful driver for the disease. By tracking when ECDNA arises and how we open the possibility of discovering a brilliance tumor early and open before this becomes aggressive and resistant to treatment. I hope this will help in the new defense in how to form and treat this cancer.

Paul Michel, PhD in Medicine, Professor of Fortinite, Professor, Professor and Vice President of Research in the Department of Pathology in Stanford Medicine, says:

“These results reveal an important new vision about the role of ECDNA in the development of the tumor and progress. It is the possibility of the possibility of electronic procedures. Increasing the possibility that the bastard tumor is another cancer may be detection and intervention earlier on the basis of ECDNA.

Director of the Great Challenges of Cancer, Dr. David Scott, says:

“This study has been embodied by bold challenges and the border science of the major challenges cancer to support them. By detecting the evolutionary history of ECDNA in an aromatic tumor, Team Edynamic does not deepen our understanding of one of the most destructive types Cancer infection.